These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15541328)

  • 21. [Renal manifestations of collagen diseases].
    Ortega Núñez A
    Bol Asoc Med P R; 1971 Jun; 63(6):148-60. PubMed ID: 5284390
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study.
    Hiraki LT; Benseler SM; Tyrrell PN; Hebert D; Harvey E; Silverman ED
    J Pediatr; 2008 Apr; 152(4):550-6. PubMed ID: 18346514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pleuropulmonary manifestations of systemic lupus erythematosus].
    Shen M; Wang Y; Xu WB; Zeng XJ; Zhang FC
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(48):3392-5. PubMed ID: 16409858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antikidney antibodies in lupus kidney disease before and after corticosteroid treatment].
    Leonardi P; Andolfatto-Zaglia G
    Minerva Med; 1965 Dec; 56(97):4283-5. PubMed ID: 5855717
    [No Abstract]   [Full Text] [Related]  

  • 25. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations.
    Frostegård J; Svenungsson E; Wu R; Gunnarsson I; Lundberg IE; Klareskog L; Hörkkö S; Witztum JL
    Arthritis Rheum; 2005 Jan; 52(1):192-200. PubMed ID: 15641060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lupus band test and disease activity in systemic lupus erythematosus: does it still matter?
    Zecević RD; Pavlović MD; Stefanović D
    Clin Exp Dermatol; 2006 May; 31(3):358-60. PubMed ID: 16681575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction.
    Goldberg A; Hammerman H; Petcherski S; Zdorovyak A; Yalonetsky S; Kapeliovich M; Agmon Y; Markiewicz W; Aronson D
    Am Heart J; 2005 Aug; 150(2):330-7. PubMed ID: 16086939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease.
    Hochman J; Urowitz MB; Ibañez D; Gladman DD
    Lupus; 2009 Apr; 18(4):313-7. PubMed ID: 19276299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stroke subtypes among young patients with systemic lupus erythematosus.
    Krishnan E
    Am J Med; 2005 Dec; 118(12):1415. PubMed ID: 16378793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Several problems of kidney disorders in SLE].
    Tojo S; Narita M; Yamaguchi K; Yoshino H; Wakashin M
    Nihon Rinsho; 1968 Dec; 26(12):3390-6. PubMed ID: 5753020
    [No Abstract]   [Full Text] [Related]  

  • 31. Renal manifestations of systemic disorders.
    Short CD; Mallick NP
    Practitioner; 1981 Jul; 225(1357):997-1005. PubMed ID: 7312776
    [No Abstract]   [Full Text] [Related]  

  • 32. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.
    Von Feldt JM; Scalzi LV; Cucchiara AJ; Morthala S; Kealey C; Flagg SD; Genin A; Van Dyke AL; Nackos E; Chander A; Gehrie E; Cron RQ; Whitehead AS
    Arthritis Rheum; 2006 Jul; 54(7):2220-7. PubMed ID: 16802358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus.
    Jeong SJ; Choi H; Lee HS; Han SH; Chin BS; Baek JH; Kim CO; Choi JY; Song YG; Kim JM
    Scand J Infect Dis; 2009; 41(4):268-74. PubMed ID: 19172435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients.
    Rabbani MA; Habib HB; Islam M; Ahmad B; Majid S; Saeed W; Shah SM; Ahmad A
    Lupus; 2009 Aug; 18(9):848-55. PubMed ID: 19578112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
    Mak A; Cheung BM; Mok CC; Leung R; Lau CS
    Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity.
    Kiani AN; Magder L; Petri M
    J Rheumatol; 2008 Jul; 35(7):1300-6. PubMed ID: 18484694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active necrotizing cerebral vasculitis in systemic lupus erythematosus.
    Goel D; Reddy SR; Sundaram C; Prayaga AK; Rajasekhar L; Narsimulu G
    Neuropathology; 2007 Dec; 27(6):561-5. PubMed ID: 18021377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Renal p-ANCA vasculitis in patients with systemic lupus erythematosus].
    Martínez-Morillo M; López R; Ibernón M; Olivé A
    Med Clin (Barc); 2011 Sep; 137(8):379-80. PubMed ID: 21145073
    [No Abstract]   [Full Text] [Related]  

  • 39. An unusual multiplex systemic lupus erythematosus family with high prevalence of nephropathy, late-onset disease, and one member with disease-onset post-HIV therapy.
    Jakez-Ocampo J; Carrillo-Maravilla E; Richaud-Patin Y; Soto-Vega E; Atisha-Fregoso Y; Llorente L
    J Clin Rheumatol; 2008 Feb; 14(1):34-7. PubMed ID: 18431097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ticlopidine-induced lupus with renal involvement.
    Ohtake T; Kobayashi S; Okamoto K; Oka M; Maesato K; Yasu T; Moriya H
    Nephrol Dial Transplant; 2006 Jul; 21(7):1992-3. PubMed ID: 16469762
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.